Also trades as: 0JDK.L (LSE) · $vol 0M
IOVA NASDAQ
Iovance Biotherapeutics, Inc.
1W: +5.1%
1M: +4.8%
3M: +28.9%
YTD: +46.8%
1Y: +93.7%
3Y: -50.6%
5Y: -85.7%
$4.11
+0.41 (+11.08%)
Weekly Expected Move ±11.0%
$3
$3
$3
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (90)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance (IOVA) Q1 2026 Earnings Transcript
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
Iovance outlines $350M-$370M 2026 revenue, while guiding Q2 total revenue to $86M-$88M
Iovance slips after Q1 miss amid in-line 2026 outlook
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates
Iovance Biotherapeutics Q1 2026 Earnings Preview
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
IOVA Stock Rises As Rival’s FDA Setback Lifts Amtagvi - StocksToTrade
IOVA Stock Draws Bullish Calls As Rival Stumbles On FDA Setback - timothysykes.com
Iovance Biotherapeutics stock hits 52-week high at 4.35 USD - Investing.com
This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street - The Motley Fool
This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street
This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street
[ARS] IOVANCE BIOTHERAPEUTICS, INC. SEC Filing - Stock Titan
IOVA Earnings History & Surprises | EPS & Revenue Results | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
Pacira (PCRX) Q1 Earnings Miss Estimates
Pacira (PCRX) Q1 Earnings Miss Estimates
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
IOVA stock slump takes Wall Street, retail by surprise — here’s why - MSN
Iovance Share Increase Proposal Weighs Dilution Risk Against TIL Growth Funding
Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates
Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
May 7 at 8:30 ET: Iovance to give Q1 results and updates - Stock Titan
Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy Now?
Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug
Chardan Maintains a Buy on Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains?
Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains? - Yahoo Finance
Iovance offers 135,470 stock options to 12 new hires - Stock Titan
Obsidian, Galera to advance cell therapy following reverse merger
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare?
Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare?
Iovance Biotherapeutics, Inc. $IOVA Shares Purchased by Aberdeen Group plc
Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? - Yahoo Finance
A Melanoma Drug Successfully Launched, Yet Iovance’s Stock Has Underperformed the Market for Three Years - NAI500
Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?
Is It Time To Reassess Iovance Biotherapeutics (IOVA) After Its Recent Share Price Surge
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Is It Time To Reassess Iovance Biotherapeutics (IOVA) After Its Recent Share Price Surge - Yahoo Finance
Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?
Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?
Analyst Sentiment Remains Strong on Iovance Biotherapeutics (IOVA) Amid U.S. Rollout of Melanoma Drug, Amtagvi
Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas
Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas - Yahoo Finance
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments
Highpeak Energy Posts Downbeat Q4 Results, Joins Netskope, Descartes Systems And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Highpeak Energy Posts Downbeat Q4 Results, Joins Netskope, Descartes Systems And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Iovance Sarcoma Trial Data Puts TIL Platform And Stock In Focus
What's Going On With Iovance Biotherapeutics Stock On Friday?
Iovance (IOVA) Hits 52-Week High as Analyst Doubles Price Target - Yahoo Finance
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036
This Unity Software Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday
Is Iovance Biotherapeutics (IOVA) Pricing Reflect Recent Cell Therapy Progress Accurately - Yahoo Finance
Iovance Biotherapeutics to Present at Upcoming Conferences
Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress
Iovance outlines surge toward profitability with 30% revenue growth in Q4 2025 while expanding Amtagvi adoption and pipeline
Iovance surges on Q4 results, Amtagvi data in soft tissue sarcoma
Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)
Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript
Iovance Biotherapeutics GAAP EPS of -$0.18 in-line, revenue of $86.71M beats by $5.7M
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?
Here are the major earnings before the open Tuesday
Iovance Biotherapeutics Q4 2025 Earnings Preview
Iovance (IOVA) Shares New Amtagvi Data, Analysts Stay Positive - Yahoo Finance
1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Rating of “Hold” from Brokerages
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH)
Iovance Biotherapeutics: Bright Prospects For 2026
Comparing Iovance Biotherapeutics (NASDAQ:IOVA) & Black Diamond Therapeutics (NASDAQ:BDTX)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
AE Wealth Management LLC Makes New Investment in Iovance Biotherapeutics, Inc. $IOVA